GMP Human Thrombopoietin Protein

• Background:

  Thrombopoietin (Tpo), is a key regulator of megakaryocytopoiesis and thrombopoiesis. It is principally produced in the liver and is bound and internalized by the receptor Tpo R/c-mpl. Defects in the Tpo-Tpo R signaling pathway are associated with a variety of platelet disorders (1-3) . The 353 amino acid (aa) human Tpo precursor is cleaved to yield the 332 aa mature protein. Mature human Tpo shares approximately 70% aa sequence homology with mouse and rat Tpo. It is an 80‑85 kDa protein that consists of an N‑terminal domain with homology to Erythropoietin (Epo) and a C‑terminal domain that contains multiple N‑linked and O-linked glycosylation sites (4,5) . Tissue specific alternate splicing of human Tpo generates multiple isoforms with internal deletions, insertions, and/or C‑terminal substitutions (6) . Tpo promotes the differentiation, proliferation, and maturation of MK and their progenitors (4,5, 7) . Several other cytokines can promote these functions as well but only in cooperation with Tpo (8,9) . Notably, IL-3 independently induces MK development, although its effects are restricted to early in the MK lineage (8,9) . Tpo additionally promotes platelet production, aggregation, ECM adhesion, and activation (10-13) . It is cleaved by platelet-derived thrombin following Arg191 within the C‑terminal domain and subsequently at other sites upon extended digestion (14) . Both full length Tpo and shorter forms circulate in the plasma, with the shorter, N‑terminal EPO-like domain forms showing significantly increased specific activity (4,5, 15) . The C‑terminal domain is not required for binding to Tpo R or inducing MK growth and differentiation (5) . Aside from its hematopoietic effects, Tpo is expressed in the brain where it promotes the apoptosis of hypoxia-sensitized neurons and inhibits neuronal differentiation by blocking NGF induced signaling (16,17) .

• Description:

  GMP Human Thrombopoietin Protein (GMP-THNH25) is expressed from human 293 cells (HEK293) . It contains AA Ser 22 - Gly 353 (Accession # P40225-1) .

• Specifications:

  This protein carries no "tag". The protein has a calculated MW of 35.5 kDa. The protein migrates as 75 kDa±5 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

• Accession Number:

  P40225-1

• Expression Region:

  Ser 22 - Gly 353

• Host:

  HEK293

• Target:

  Thrombopoietin

• Conjugation:

  Unconjugated

• Tag:

  Native

• Stability:

  ● -20°C to -70°C for 5 years in lyophilized state; ● -70°C for 12 months under sterile conditions after reconstitution. Upon receipt, store it immediately at -20°C or lower for long term storage.

• Endotoxin:

  10 EU/mg

• Purity:

  95%

• Format:

  Powder-GMP

• Buffer:

  20 mM NaAc-HAc, pH5.0

• Molecular Weight:

  35.5 kDa

• Shipping Conditions:

  Blue ice

• Storage Conditions:

  -20°C

• Package Size:

  50ug*200

• Species:

  Human